Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24501868 | 1.00 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1CYP2C9 | |
| SCHEMBL13003596 | 1.00 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1CYP2C9 | |
| SCHEMBL18927429 | 0.84 | KMT2A (0.40) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL21275431 | 0.82 | TAAR1 (0.47) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL29640790 | 0.82 | TAAR1 (0.47) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL23242089 | 0.82 | TAAR1 (0.47) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL14217551 | 0.82 | TAAR1 (0.47) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL20718221 | 0.81 | KMT2A (0.38) | KMT2AMEN1LMNAP2RX7HRH1 | |
| SCHEMBL20032334 | 0.81 | P2RX7 (0.40) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL20389049 | 0.80 | KMT2A (0.37) | KMT2AMEN1LMNAP2RX7HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-2970155-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL MYERS SQUIBB CO (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-20120232048-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-20120232048-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8178561-B2 | Method for modulating GPR119 G protein-coupled receptor and selected compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2173737-B1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110190327-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190327-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-7928230-B2 | Method for modulating GPR119 G protein-coupled receptor and selected compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928230-B2 | Method for modulating GPR119 G protein-coupled receptor and selected compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100323887-A1 | MESOIONIC PESTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| WO-2009012277-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190327-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | KMT2A 3559/4885MEN1 2862/4885LMNA 4695/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KMT2A 3974/4885MEN1 1948/4885LMNA 1249/4885 |
| US-20120232048-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | KMT2A 3559/4885MEN1 2862/4885LMNA 4695/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | KMT2A 1610/4885MEN1 629/4885LMNA 2851/4885 |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | KMT2A 110/4885MEN1 4054/4885LMNA 1237/4885 |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | KMT2A 3559/4885MEN1 2862/4885LMNA 4695/4885 |
| US-20100323887-A1 | MESOIONIC PESTICIDES | DDT, CHRM1, CHRM3 | KMT2A 3136/4885MEN1 255/4885LMNA 4228/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KMT2A 1870/4885MEN1 3209/4885LMNA 3512/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | KMT2A 97/4885MEN1 3551/4885LMNA 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.